MA53817A - Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv - Google Patents

Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv

Info

Publication number
MA53817A
MA53817A MA053817A MA53817A MA53817A MA 53817 A MA53817 A MA 53817A MA 053817 A MA053817 A MA 053817A MA 53817 A MA53817 A MA 53817A MA 53817 A MA53817 A MA 53817A
Authority
MA
Morocco
Prior art keywords
biphenyl
treatment
type
sulfonamide compounds
collagen diseases
Prior art date
Application number
MA053817A
Other languages
English (en)
French (fr)
Inventor
Celia Jenkinson
Radko Komers
Original Assignee
Travere Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Travere Therapeutics Inc filed Critical Travere Therapeutics Inc
Publication of MA53817A publication Critical patent/MA53817A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MA053817A 2018-10-04 2019-10-03 Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv MA53817A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862741270P 2018-10-04 2018-10-04
US201962853904P 2019-05-29 2019-05-29
US201962894559P 2019-08-30 2019-08-30

Publications (1)

Publication Number Publication Date
MA53817A true MA53817A (fr) 2021-08-11

Family

ID=68318947

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053817A MA53817A (fr) 2018-10-04 2019-10-03 Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv

Country Status (13)

Country Link
US (1) US11207299B2 (https=)
EP (1) EP3860594B1 (https=)
JP (2) JP7524167B2 (https=)
KR (1) KR102902972B1 (https=)
CN (1) CN113286587A (https=)
AU (1) AU2019354784B2 (https=)
BR (1) BR112021006132A2 (https=)
CA (1) CA3114434A1 (https=)
ES (1) ES3057657T3 (https=)
IL (1) IL281965B1 (https=)
MA (1) MA53817A (https=)
MX (1) MX2021003606A (https=)
WO (1) WO2020072814A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117017985A (zh) 2016-10-13 2023-11-10 特拉维尔治疗公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
WO2022246200A1 (en) * 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
WO2022266370A1 (en) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
JP2025183466A (ja) * 2022-11-11 2025-12-17 株式会社アークメディスン 化合物、エンドセリンa受容体拮抗剤、アンジオテンシンiiタイプ1受容体拮抗剤及び医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
HUP0104634A3 (en) 1998-07-06 2002-11-28 Bristol Myers Squibb Co Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
ATE339417T1 (de) 1999-12-15 2006-10-15 Bristol Myers Squibb Co Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2010135350A2 (en) 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
CA2958585C (en) * 2014-08-21 2024-01-09 Stealth Biotherapeutics Corp Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome
EP3515501A1 (en) * 2016-09-19 2019-07-31 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
CN117017985A (zh) * 2016-10-13 2023-11-10 特拉维尔治疗公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
US20220048900A1 (en) 2018-12-21 2022-02-17 Travere Therapuetics, Inc. Amorphous sparsentan compositions

Also Published As

Publication number Publication date
JP7524167B2 (ja) 2024-07-29
MX2021003606A (es) 2021-08-16
BR112021006132A2 (pt) 2021-07-20
US20200147050A1 (en) 2020-05-14
JP2024133735A (ja) 2024-10-02
CN113286587A (zh) 2021-08-20
EP3860594B1 (en) 2025-10-01
CA3114434A1 (en) 2020-04-09
AU2019354784A1 (en) 2021-04-15
IL281965A (en) 2021-05-31
WO2020072814A1 (en) 2020-04-09
JP2022514152A (ja) 2022-02-10
AU2019354784B2 (en) 2025-07-10
IL281965B1 (en) 2026-04-01
US11207299B2 (en) 2021-12-28
ES3057657T3 (en) 2026-03-03
KR20210081338A (ko) 2021-07-01
KR102902972B1 (ko) 2025-12-22
EP3860594A1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA55974A (fr) Composés triaryles pour le traitement de maladies pd-l1
EP3411380A4 (en) Compounds for treating eye disorders or diseases
MA52003A (fr) Procédés de traitement de maladies associées au hpv
EP4045037C0 (en) HETEROARYL-BIPHENYL-AMINE FOR THE TREATMENT OF PD-L1 DISEASES
EP3448875A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) COMPOSITIONS FOR TREATING A DISEASE
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3866781A4 (en) NOVEL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP3890725A4 (en) COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES
EP3621973A4 (en) COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND USES THEREOF
MA41841A (fr) Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
MA49141A (fr) Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
MA53817A (fr) Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv
EP3273955A4 (en) TREATMENT OF RESPIRATORY DISEASES
EP3866777A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF INFLAMMATORY DISEASES
MA53127A (fr) Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales
EP3877382A4 (en) NOVEL COMPOUNDS TO TREAT RESPIRATORY DISEASES
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
EP3593803A4 (en) COMPOUNDS FOR TREATING DISEASES CAUSED BY OXALATE ACCUMULATION
EP3316887A4 (en) GLS1-INHIBITOR TO TREAT DISEASES
EP3737363A4 (en) METHODS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES
EP3373931A4 (en) HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES